Kristi Rosa
Associate Editorial Director at OncLive
associate editorial director for @OncLive. bibliophile. cat mom. tweets are my own.
Articles
FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
1 week ago |
onclive.com | Kristi Rosa
The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja Co-pack) for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously received systemic therapy. The regulatory decision was supported by data from RAMP-201 (NCT04625270), which showed that the doublet elicited a confirmed overall response rate of 44% (95% CI, 31%-58%) with a duration of response (DOR) that ranged from 3.3 months to 31.1 months.
-
1 week ago |
onclive.com | Kristi Rosa
Ultra-low prostate-specific antigen (PSA) responses were linked with improved clinical outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide (Nubeqa) plus androgen deprivation therapy (ADT), according to data from post hoc analyses of the phase 3 ARANOTE study (NCT04736199) presented during the 2025 AUA Annual Meeting.1 Those with ultra-low PSA under .02 ng/mL at any time were found to have lower risk of radiological progression or death vs...
-
1 week ago |
onclive.com | Kristi Rosa
Botensilimab paired with balstilimab induced responses with a manageable toxicity profile in patients with treatment-refractory hepatocellular carcinoma (HCC), according to findings from the first-in-human, phase 1 C-800-01 study (NCT03860272) presented during the 2025 AACR Annual Meeting.1 In evaluable patients (n = 18), the doublet elicited an objective response rate (ORR) of 17% (95% CI, 4%-41%) with best overall responses of partial response in 17% of patients, stable disease in 56% of...
-
1 week ago |
cancernetwork.com | Kristi Rosa
For patients with recurrent low-grade intermediate-risk non–muscle-invasive bladder cancer (NMIBC), UGN-102 elicited a complete response (CR) rates, as well as positive tolerability, according to 18-month follow-up data from the phase 3 ENVISION trial (NCT05243550) presented at the 2025 American Urological Association Annual Meeting.1 Previously, it was reported that the primary end point of CR at 3 months was achieved by 79.6% (95% CI, 73.9%-84.5%) of those who received UGN-102 (n =...
-
2 weeks ago |
onclive.com | Kristi Rosa
Below is your guide to all the oncologic therapeutic options approved by the FDA in April 2025. The roundup provides everything you need to know, right at your fingertips—all the topline findings that supported the decisions and expert insights detailing what they mean for clinical practice.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 435
- Tweets
- 1K
- DMs Open
- No